Skip Navigation LinksHome > January 2012 - Volume 31 - Issue 1 > Safety and Immunogenicity of Quadrivalent Meningococcal Conj...
Pediatric Infectious Disease Journal:
doi: 10.1097/INF.0b013e318236c67b
HIV Reports

Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in 2- to 10-year-old Human Immunodeficiency Virus-infected Children

Siberry, George K. MD, MPH*; Warshaw, Meredith G. MSS, MA; Williams, Paige L. MS, PhD; Spector, Stephen A. MD; Decker, Michael D. MD, MPH§; Jean-Philippe, Patrick MD; Yogev, Ram MD; Heckman, Barbara E. BS**; Manzella, Adam MA**; Roa, Jhoanna MD††; Nachman, Sharon MD‡,‡; Lujan-Zilbermann, Jorge MD§,§; for the IMPAACT P1065 Protocol Team

Supplemental Author Material
Collapse Box


Background: Human immunodeficiency virus (HIV)-infected children are at increased risk of meningococcal infection and poor response to quadrivalent meningococcal conjugate vaccine (MCV4), but MCV4 has not been studied in preadolescent HIV-infected children.

Methods: The P1065 trial enrolled 2- to 10-year-old HIV-infected children with CD4 ≥25% to receive MCV4 at entry and at week 24. Rates of response (≥4-fold increase in rabbit serum bactericidal antibody) against each meningococcal serogroup (A, C, Y, W-135), geometric mean titers, and rates of seroprotection (rabbit serum bactericidal antibody titer ≥1:128) were determined from sera obtained at entry and weeks 4, 24, 28, and 72. Adverse events were assessed for 6 weeks after each MCV4 dose.

Results: At entry, 47% of the 59 participants were male, 56% black, 31% Latino, median age was 6 years, 88% were receiving antiretroviral therapy, and 75% had viral load <400 copies/mL. There were no serious adverse events within 6 weeks after MCV4 doses; all vaccination reactions were mild. Response after a single MCV4 dose was high to serogroup A (92%) and W-135 (98%); responses improved after a second dose for serogroup C (43%–80%) (P < 0.0001) and Y (76%–84%) (P = 0.38). By week 72, seroprotection rates were 93%, 91%, 78%, and 46% for serogroups W-135, Y, A, and C, respectively.

Conclusions: Two doses of MCV4 were safe and immunogenic in 2- to 10-year-old HIV-infected children. The second dose increased the proportion of children who made a response to serogroup C. Seroprotection waned substantially for serogroups A and C within 1 year of last MCV4 dose.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.